Humacyte, Inc. (HUMA)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$0.44+5.40%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Humacyte, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	1.84M
EPS	—	-0.092
Annual ending 2026-12-31
Revenue	—	3.5M
EPS	—	-0.414
Annual ending 2027-12-31
Revenue	—	21.74M
EPS	—	-0.277

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain Nasdaq listing by meeting minimum bid price	Management is addressing Nasdaq listing compliance to maintain its listing.	Broken	Fails to maintain minimum bid price required by Nasdaq	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 quarters including 2026-Q2 and 2026-Q3. The company received Nasdaq notices in May and July 2026 regarding bid price below $1.00 per share for continued listing. This regulatory challenge remains unresolved as of the latest disclosures, indicating ongoing compliance efforts but no resolution yet. Delivery assessment Oct 24, 2026
Improve financial stability via capital raises	The company raised $50 million in a public offering to improve financial stability.	Improving	Fails to secure capital or liquidity runs critically low	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 quarters including 2026-Q1 and 2026-Q2. The company raised $57.5 million gross proceeds from a public offering in June 2026 to fund commercialization, regulatory filings, and pipeline development. This capital raise supports financial stability and aligns with management's stated priorities. Delivery assessment Oct 24, 2026
Expand strategic partnerships to boost market reach	Humacyte expands strategic partnerships, like the VA hospital contract.	Improving	Revenue growth falls below $6 million in FY26	Revenue: $406,000 FY2026-Q2; GAAP. Published target: Revenue grows to >=$26 million in FY27. Target period is not explicitly aligned with this observation. Source published Aug 12, 2026406,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 755e1b92-d0e1-4499-8a27-1322e0861f26. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenueUnavailable

Unavailable → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	3 / 4
2026-07-25	Unavailable	Unavailable	3 / 4
2026-07-26	Unavailable	Unavailable	3 / 4
2026-07-27	Unavailable	Unavailable	3 / 4
2026-07-28	Unavailable	Unavailable	3 / 4
2026-07-29	Unavailable	$26,305,400	3 / 5
2026-07-30	Unavailable	Unavailable	3 / 4
2026-07-31	Unavailable	$26,305,400	3 / 5
2026-08-01	Unavailable	Unavailable	3 / 4
2026-08-02	Unavailable	$26,305,400	3 / 5
2026-08-03	Unavailable	Unavailable	3 / 4
2026-08-04	Unavailable	$26,305,400	3 / 5
2026-08-05	Unavailable	Unavailable	3 / 4
2026-08-06	Unavailable	$26,305,400	3 / 5
2026-08-07	Unavailable	Unavailable	3 / 4
2026-08-08	Unavailable	$26,305,400	3 / 5
2026-08-09	Unavailable	$26,305,400	3 / 5
2026-08-10	Unavailable	$26,305,400	3 / 5
2026-08-12	Unavailable	$26,305,400	3 / 5
2026-08-13	Unavailable	$26,305,400	3 / 5
2026-08-14	Unavailable	Unavailable	3 / 4
2026-08-15	Unavailable	Unavailable	4 / 4
2026-08-16	Unavailable	Unavailable	4 / 4
2026-08-17	Unavailable	Unavailable	4 / 4
2026-08-18	Unavailable	Unavailable	4 / 4
2026-08-19	Unavailable	Unavailable	4 / 4
2026-08-20	Unavailable	Unavailable	4 / 4
2026-08-21	Unavailable	Unavailable	4 / 4
2026-08-22	Unavailable	Unavailable	4 / 4
2026-08-23	Unavailable	Unavailable	4 / 4
2026-08-24	Unavailable	Unavailable	4 / 4
2026-08-25	Unavailable	Unavailable	4 / 4
2026-08-26	Unavailable	Unavailable	4 / 4
2026-08-27	Unavailable	Unavailable	4 / 4
2026-08-28	Unavailable	Unavailable	4 / 4
2026-08-29	Unavailable	Unavailable	4 / 4
2026-08-30	Unavailable	Unavailable	4 / 4
2026-08-31	Unavailable	Unavailable	4 / 4
2026-09-01	Unavailable	Unavailable	4 / 4
2026-09-02	Unavailable	Unavailable	4 / 4
2026-09-03	Unavailable	Unavailable	4 / 4
2026-09-04	Unavailable	Unavailable	4 / 4
2026-09-05	Unavailable	Unavailable	4 / 4
2026-09-06	Unavailable	Unavailable	4 / 4
2026-09-07	Unavailable	Unavailable	4 / 4
2026-09-08	Unavailable	Unavailable	4 / 4
2026-09-09	Unavailable	Unavailable	4 / 4
2026-09-10	Unavailable	Unavailable	4 / 4
2026-09-11	Unavailable	Unavailable	4 / 4
2026-09-12	Unavailable	Unavailable	4 / 4
2026-09-13	Unavailable	Unavailable	4 / 4
2026-09-14	Unavailable	Unavailable	4 / 4
2026-09-15	Unavailable	Unavailable	4 / 4
2026-09-16	Unavailable	Unavailable	4 / 4
2026-09-17	Unavailable	Unavailable	4 / 4
2026-09-18	Unavailable	Unavailable	4 / 4
2026-09-19	Unavailable	Unavailable	4 / 4
2026-09-20	Unavailable	Unavailable	4 / 4
2026-09-21	Unavailable	Unavailable	4 / 4
2026-09-22	Unavailable	Unavailable	4 / 4
2026-09-23	Unavailable	Unavailable	4 / 4
2026-09-24	Unavailable	Unavailable	4 / 4
2026-09-25	Unavailable	Unavailable	4 / 4
2026-09-26	Unavailable	Unavailable	4 / 4
2026-09-27	Unavailable	Unavailable	4 / 4
2026-09-28	Unavailable	Unavailable	4 / 4
2026-09-29	Unavailable	Unavailable	4 / 4
2026-09-30	Unavailable	Unavailable	4 / 4
2026-10-01	Unavailable	Unavailable	4 / 4
2026-10-02	Unavailable	Unavailable	4 / 4
2026-10-03	Unavailable	Unavailable	4 / 4
2026-10-04	Unavailable	Unavailable	4 / 4
2026-10-05	Unavailable	Unavailable	4 / 4
2026-10-06	Unavailable	Unavailable	4 / 4
2026-10-07	Unavailable	Unavailable	4 / 4
2026-10-08	Unavailable	Unavailable	4 / 4
2026-10-09	Unavailable	Unavailable	4 / 4
2026-10-10	Unavailable	Unavailable	4 / 4
2026-10-11	Unavailable	Unavailable	4 / 4
2026-10-12	Unavailable	Unavailable	4 / 4
2026-10-13	Unavailable	Unavailable	4 / 4
2026-10-14	Unavailable	Unavailable	4 / 4
2026-10-15	Unavailable	Unavailable	4 / 4
2026-10-16	Unavailable	Unavailable	4 / 4
2026-10-17	Unavailable	Unavailable	4 / 4
2026-10-18	Unavailable	Unavailable	4 / 4
2026-10-19	Unavailable	Unavailable	4 / 4
2026-10-20	Unavailable	Unavailable	4 / 4
2026-10-21	Unavailable	Unavailable	4 / 4
2026-10-22	Unavailable	Unavailable	4 / 4
2026-10-23	Unavailable	Unavailable	4 / 4
2026-10-24	Unavailable	Unavailable	4 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	6	1
2026-06-01	4	1
2026-07-01	4	1
2026-08-01	4	1
2026-09-01	4	1
2026-10-01	4	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 4 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Williams TradingOct 16

$1.00New observation · no comparable prior

$0$0.55$1.10

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain Nasdaq listing by meeting minimum bid pricePublished status: Broken
Improve financial stability via capital raisesDirect metric needs a verified mapping
Expand strategic partnerships to boost market reachRevenue: $406,000

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.3%Typical daily move · historical

Downside history

-79.3%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Humacyte, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative growth story, not an established earnings compounder: the company is loss-making, management execution is volatile, and risk is elevated. The long-term thesis is in a watch state, with medium confidence and recent performance below its industry cohort.

What's priced into Humacyte, Inc.

HUMA is valued at a premium to peers, with the valuation case resting on future potential rather than current profits. The valuation model has low confidence, and the evidence does not show that investors already price in the full combination of weak results and execution turbulence.

What the fundamentals likely do

Near term, an earnings miss is a material risk, and a recent earnings miss adds to that concern. Over the multi-year view, Symvess sales have grown from a small base, while management plans a supplemental ATEV filing in the second half of 2026; Nasdaq listing compliance remains unresolved.

What Humacyte, Inc. hinges on

The thesis depends on whether commercialization and regulatory filings continue to advance and become meaningful business progress. It also hinges on resolving listing compliance and on the Healthcare backdrop: weakening jobs data or weaker sector bellwethers could weigh on the setting, while continued strong results from those companies could sustain a sector tailwind.